Acceleron pharma inc (XLRN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Operating Activities
Net loss

-124,858

-118,871

-108,454

-57,014

-63,894

-51,259

-21,898

-32,582

36,266

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

3,900

3,700

2,800

1,676

1,176

1,118

915

1,293

3,134

Loss on disposition of fixed assets

-

-

-

-

-

-25

-32

0

-

Stock-based compensation

22,995

24,569

28,248

18,557

12,075

4,778

2,196

1,206

1,427

Accretion of deferred interest

-

-

-

-

-

-536

342

335

271

Amortization of deferred debt issuance costs

-

-

-

-

-

36

186

84

79

Change in fair value of warrants

-

-

-

-7,262

3,528

-5,037

26,875

2,258

481

Net amortization of premium on investments

-

-

-

-

-

0

0

51

162

Other non-cash items

-128

-409

-1,168

8

372

-

-

-

-

Gain on retirement of warrants

-

-

-

-

-

-

76

0

-

Forgiveness of related party receivable

-

-

-

-

-

-

237

0

-

Changes in assets and liabilities:
Prepaid expenses and other assets

2,429

2,986

675

1,411

-7

255

823

594

-2,564

Collaboration receivables (all amounts are with a related party)

1,508

3,470

336

-394

261

-249

840

1,116

-1,836

Non-cash lease expense

5,143

0

0

-

-

-

-

-

-

Related party receivable

-

-

-

-

-

-

4

8

6

Accounts payable

1,876

-673

-504

644

151

-161

-53

-1,272

334

Accrued expenses

6,258

1,904

1,493

524

4,976

-17

709

1,640

-2,773

Operating lease obligations

5,333

-

-

-

-

-

-

-

-

Other changes in operating assets and liabilities

17

-665

309

-

-

-

-

-

-

Deferred revenue

-

-

-

-549

-1,184

-1,673

-26,949

-9,696

-35,130

Deferred rent

-

-

-

96

519

499

499

482

-211

Restricted cash

-

-

-

-

-106

-11

0

1

-200

Net cash used in operating activities

-93,804

-94,706

-76,544

-44,545

-44,211

-53,220

-19,650

-38,884

9,056

Investing Activities
Purchases of investments

395,138

73,570

179,935

218,314

134,697

0

0

-

-

Proceeds from sales and maturities of investments

327,134

199,087

119,965

112,889

26,685

0

0

-

-

Purchases of property and equipment

3,287

2,590

4,396

3,380

959

514

307

441

27

Net cash provided by (used in) investing activities

-71,291

122,927

-64,366

-108,805

-108,971

-514

-307

-441

-27

Financing Activities
Payments made to repurchase redeemable convertible preferred stock, common stock and warrants to purchase common stock

-

-

-

-

-

-

300

0

-

Proceeds from issuance of common stock from public offering, net of issuance costs

248,130

0

215,802

140,697

-47

129,174

0

-

-

Payments for withholding taxes on restricted stock units

-

-

-

0

0

-

-

-

-

Proceeds from long-term debt, net of issuance costs

-

-

-

-

-

-

-

19,935

-

Proceeds from issuance of common stock from public offering, net of issuance costs

-

-

-

-

-

-

86,825

0

30,378

Proceeds from issuance of common stock from private placements

-

-

-

-

-

-

10,000

0

-

Payments of long-term debt

-

-

-

-

-

16,331

3,669

6,191

9,476

Proceeds from issuances of common stock related to employee stock purchase plan

-

-

-

658

589

0

-

-

-

Proceeds from exercise of stock options and warrants to purchase common stock

-

-

-

5,312

3,963

4,188

653

155

190

Payments for capital lease expenditures

0

139

0

0

-

-

-

-

-

Net proceeds from exercises and vesting of stock awards, ESPP contributions, and exercise of warrants to purchase common stock

10,590

16,285

4,494

-

-

-

-

-

-

Net cash provided by financing activities

258,720

16,146

220,296

146,667

4,505

117,031

93,509

13,899

21,092

Net increase in cash, cash equivalents and restricted cash

93,625

44,367

79,386

-6,683

-148,677

63,297

73,552

-25,426

30,121

Supplemental Disclosure of Cash Flow Information:
Cash paid for interest

-

-

-

-

-

1,574

1,657

1,065

1,461

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Accretion of dividends, interest, redemption value, and issuance costs on preferred stock

-

-

-

-

-

-

19,870

27,061

21,757

Conversion of preferred stock into common stock

-

-

-

-

-

-

286,094

0

-

Conversion of preferred stock warrants into common stock warrants

-

-

-

-

-

-

2,012

0

-

Cashless exercise of warrants

0

797

0

8,682

465

11,592

678

0

-

Capitalized follow-on public offering costs included in accrued expenses

0

221

0

0

306

0

74

0

-

Purchase of property and equipment included in accounts payable and accrued expenses

444

1,159

194

397

270

11

297

0

-